• S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?

  • Apr 4 2023
  • Durée: 24 min
  • Podcast

Page de couverture de S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?

S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982422). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline https://pubmed.ncbi.nlm.nih.gov/35486072/

    Health-Related Quality of Life and Symptoms in Patients With IPF Treated With Nintedanib: Analyses of Patient-Reported Outcomes From the INPULSIS® Trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/

    Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089322/
    Voir plus Voir moins
activate_primeday_promo_in_buybox_DT
Troubles et maladies Hygiene & Healthy Living Science
Voir plus Voir moins

Ce que les auditeurs disent de S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.